» Articles » PMID: 30646912

Role of the Tumor Microenvironment in PD-L1/PD-1-mediated Tumor Immune Escape

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2019 Jan 17
PMID 30646912
Citations 657
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor immune escape is an important strategy of tumor survival. There are many mechanisms of tumor immune escape, including immunosuppression, which has become a research hotspot in recent years. The programmed death ligand-1/programmed death-1 (PD-L1/PD-1) signaling pathway is an important component of tumor immunosuppression, which can inhibit the activation of T lymphocytes and enhance the immune tolerance of tumor cells, thereby achieving tumor immune escape. Therefore, targeting the PD-L1/PD-1 pathway is an attractive strategy for cancer treatment; however, the therapeutic effectiveness of PD-L1/PD-1 remains poor. This situation requires gaining a deeper understanding of the complex and varied molecular mechanisms and factors driving the expression and activation of the PD-L1/PD-1 signaling pathway. In this review, we summarize the regulation mechanisms of the PD-L1/PD-1 signaling pathway in the tumor microenvironment and their roles in mediating tumor escape. Overall, the evidence accumulated to date suggests that induction of PD-L1 by inflammatory factors in the tumor microenvironment may be one of the most important factors affecting the therapeutic efficiency of PD-L1/PD-1 blocking.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.


Endophytic Fungal Diversity and Its Interaction Mechanism with Medicinal Plants.

Gao Y, Xu Y, Dong Z, Guo Y, Luo J, Wang F Molecules. 2025; 30(5).

PMID: 40076252 PMC: 11902086. DOI: 10.3390/molecules30051028.


Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer.

Vo M, Nguyen V, Tran V, Oh H, Jung S, Bae W Cancer Immunol Immunother. 2025; 74(4):143.

PMID: 40056167 PMC: 11890499. DOI: 10.1007/s00262-025-03997-2.


Tumor-intrinsic PRMT5 upregulates FGL1 methylating TCF12 to inhibit CD8 T-cell-mediated antitumor immunity in liver cancer.

Sun J, Yuan H, Sun L, Zhao L, Wang Y, Hou C Acta Pharm Sin B. 2025; 15(1):188-204.

PMID: 40041915 PMC: 11873606. DOI: 10.1016/j.apsb.2024.10.016.


HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization.

Han R, Luo Y, Gao J, Zhou H, Wang Y, Chen J Vaccines (Basel). 2025; 13(2).

PMID: 40006729 PMC: 11860249. DOI: 10.3390/vaccines13020182.


References
1.
Ni X, Sui H, Liu Y, Ke S, Wang Y, Gao F . TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep. 2012; 28(2):615-21. DOI: 10.3892/or.2012.1822. View

2.
Tang Y, He Y, Shi L, Yang L, Wang J, Lian Y . Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017; 8(24):39001-39011. PMC: 5503590. DOI: 10.18632/oncotarget.16545. View

3.
Tu C, Zeng Z, Qi P, Li X, Guo C, Xiong F . Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing. Carcinogenesis. 2018; 39(12):1517-1528. DOI: 10.1093/carcin/bgy108. View

4.
Bommarito D, Hall C, Taams L, Corrigall V . Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 2017; 188(3):455-466. PMC: 5422858. DOI: 10.1111/cei.12949. View

5.
Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View